Description du projet
Un réseau de formation en vaccination lutte contre la résistance sociétale et bactérienne
La résistance aux antimicrobiens a pris des proportions démesurées. Simultanément, un nombre croissant de personnes sont devenues résistantes à la vaccination. Les scientifiques sont de plus en plus appelés pour défendre toutes sortes de problèmes de société, délaissant leurs blouses blanches et leurs laboratoires à l’abri du public pour se placer sous les projecteurs. C’est exactement ce que BactiVax a l’intention de faire. Ce projet aborde le développement de vaccins contre les infections bactériennes tout au long du processus allant de la découverte des antigènes à l’administration des vaccins. Toutefois, son impact ne se limitera pas au développement scientifique. L’équipe a fait de la sensibilisation et de l’engagement du public la clé de voute de sa recherche et, dans le cadre d’un réseau de formation sur les vaccins bactériens, des chercheurs en début de carrière porteront la double casquette de scientifiques et d’avocats des vaccins auprès du public.
Objectif
BactiVax (anti-Bacterial Innovative Vaccine Training Network) is a European training network (ETN) that will provide high-level training in vaccinology to a new generation of 15 high-achieving, early-stage researchers (ESRs). This innovative ETN uniquely blends cutting-edge research training, non-academic placements and transferable skills. It will develop strong entrepreneurial and creative mindsets. BactiVax will train ESRs in a broad range of transferable skills enabling them to thrive in careers in vaccine research within academia and/or industry through discovery, development, and delivery of innovative therapeutic and prophylactic vaccines. The World Health Organisation has identified antimicrobial resistance (AMR) as one of the three greatest threats to mankind. There is a urgent need to train innovative ESRs in the development of new vaccines against AMR infections. BactiVax will tackle the societal challenge caused by the emergence of AMR pathogens and have significant impact on pathogens causing chronic, life-threatening respiratory and/or systemic infections. BactiVax training will cover critical areas of vaccinology from early antigen discovery to optimisation of host response and delivery of vaccine antigens. It will also encompass the increasing problem of vaccine hesitancy in its public engagement. The specific research objectives are to: 1) Identify novel, protective vaccine antigens against target pathogens; 2) Optimise the host response to vaccines; 3) Optimise vaccine delivery; 4) Lead on vaccine advocacy. BactiVax includes 2 SME beneficiaries, a multinational vaccine company and 4 SMEs as partners all of whom are involved in training, entrepreneurship, commercial vaccine development and vaccine antigen processing. All ESRs will have secondments in non-academic environment to enhance their exposure to the commercial. Overall, BactiVax will provide ESRs with rich experience and advanced multidisciplinary skills in the cutting edge area of vaccines
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Coordinateur
4 Dublin
Irlande